Пошуковий запит: <.>K=КАФЕДРА ВНУТРІШНІХ ХВОРОБ № 2<.> |
Загальна кількість знайдених документів : 272
Показані документи с 1 за 20 |
|
1.
| Growth differentiation factor-15 in heart failure: new update of clinical relevance/A. E. Berezin, V. Poliasnyi, L. A. Kovalevskaya, A. A. Berezin // Sapporo Igaku Zasshi. Sapporo Medical Journal. -Sapporo:Sapporo medical univ, 2021. т.Vol. 55,N Iss. 7.-С.P. 1-10
|
2.
| The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy/A. Topf, M. Mirna, B. Ohnewein, P. Jirak, K. Kopp, D. Fejzic, M. Haslinger, L. J. Motloch, U. C. Hoppe, A. Berezin, M. Lichtenauer // Frontiers in Cardiovascular Medicine. -Lausanne, 2020. т.Vol. 7.- Ст.Article 579567
|
3.
| Berezin A. A. Irisin predicted heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus/A. Berezin, I. M. Fushtey, A. Berezin // Diabetes Technology & Therapeutics. -Нью-Йорк, 2022. т.Vol. 24.-С.A151-A151
|
4.
| Berezin A. A. Multidirectional changes in the levels of irisin and apelin predicted heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus/A. A. Berezin, I. M. Fushtey, A. E. Berezin // Diabetes Technology & Therapeutics. -Нью-Йорк, 2022. т.Vol. 24.-С.A150-A150
|
5.
| The role of single nucleotide polymorphism of val66met (rs6265) of the brain-derived neurotropic factor in formation of endpoints after st-segment elevation myocardial infarction/O. V. Petyunina, M. P. Kopytsya, A. Е. Berezin, A. А. Berezin // European Heart Journal:Oxford University Press, 2020. т.Vol. 41,N Issue Supplement_2.- Ст.ehaa946.1676
|
6.
| Petyunina O. V. Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention/O. V. Petyunina, M. P. Kopytsya, A. E. Berezin // Biomedical Research And Therapy:Ho Chi Minh City, 2020:Vol. 7,N N 8.-С.P. 3921-3932
|
7.
| Subclinical emotional distress predicts 6-month clinical outcomes after ST-segment elevation myocardial infarction/O. V. Petyunina, M. P. Kopytsya, A. E. Berezin, O. V. Skrynnyk // Future Cardiology. -London:Future medicine LTD, 2020. т.Vol. 16,N N 5.-С.P. 457-467
|
8.
| Berezin A. E. Challenging and opportunities in clinical implementation of circulating cardiac biomarkers in diabetes mellitus: the narrative review/A. E. Berezin, A. А. Berezin // AME medical journal, 2021. т.Vol. 6,N June.- Ст.18
|
9.
| Berezin A. E. Signature of standard modifiable CV factors as unrecognizable risk factor of in-hospital mortality in patients with acute myocardial infarction/A. E. Berezin // International Journal of Cardiology, 2023. т.Vol. 371.-С.71-73
|
10.
| Macrophage Migration Inhibitory Factor Levels Predict No-reflow in ST-segment Elevation Myocardial Infarction/T. Y.Storozhenko, I. R. Vishnevskaya, M. P. Kopytsya, A. E. Berezin // Pharmacophore. -Bari:Jadoun science publishing group, 2021. т.Vol. 12,N N 4.-С.P. 56-67
|
11.
| Berezin A. E. Reversibility of adverse cardiac remodeling in type 2 diabetes mellitus patients: focus on sodium-glucose cotransporter-2 inhibitors/A. E. Berezin, A. A. Berezin // Vessel Plus, 2022. т.Vol. 6.-С.56
|
12.
| Berezin A. E. Altered profile of circulating myokines as a predictor of poor prognosis in heart failure/A. E. Berezin, A. А. Berezin, S. P. Myrnyi // Transylvanian review:Center Transylvanian Studies, 2020. т.Vol. 27,N N 50.-С.P.15417-15422
|
13.
| The macrophage migration inhibitory factor as a predictive biomarker of one-year adverse clinical outcomes in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention/T. Y. Storozhenko, Iryna R. Vyshnevska, M. P. Kopytsya, A. E. Berezin // Sapporo Igaku Zasshi. Sapporo Medical Journal. -Sapporo:Sapporo medical univ, 2021. т.Vol. 55,N Iss. 10.-С.P. 1-14
|
14.
| Prognostication of Heart Failure Evolution: From Circulating Biomarkers to Genetic Risk Predictive Score/A. E. Berezin, B. Peterlin , M. Lichtenauer, I. Mozos // Frontiers in Cardiovascular Medicine. -Lausanne, 2021. т.Vol. 8.- Ст.Article 687232
|
15.
| Berezin A. E. Cell-free long noncoding RNAs as predictive biomarkers for cardiovascular diseases/A. E. Berezin // International Journal of Cardiology, 2022. т.Vol. 359.-С.115-117
|
16.
| Fetuin-A as Metabolic Biomarker in Patients at Higher Risk of Heart Failure/А. A. Berezin, V. A. Poliasnyi, L. A. Kovalevskaya, S. A. Ivanchenko, A. Pahlevanzade, P. K. Panigrahi, A. E. Berezin // Journal of Biochemical Technology:Sevas Publishing, 2021. т.Vol. 12,N N 3.-С.P. 59-66
|
17.
| Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus/A. А. Berezin, M. Lichtenauer, E. Boxhammer, I. M. Fushtey, A. E. Berezin // Frontiers in Physiology, 2022. т.Vol. 13.-С.922775
|
18.
| Berezin A. E. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium–glucose co-transporter 2 inhibitors?/A. E. Berezin, A. А. Berezin // Future Cardiology. -London:Future medicine LTD, 2021. т.Vol. 17,N N 3.-С.P. 497-506
|
19.
| The Hormone-like Myokines Irisin as Novel Biomarker for Cardiovascular Risk Stratification/A. А. Berezin, D. P. Myrnyi, S. P. Myrnyi, A. E. Berezin // Pharmacophore. -Bari:Jadoun science publishing group, 2021. т.Vol. 12,N N 1.-С.P. 44-50
|
20.
| Berezin A. E. Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review/A. E. Berezin, A. А. Berezin // Diabetes Therapy. -London:Springer, 2020. т.Vol. 11,N N 6.-С.P.1271–1291
|
|
|
|
На головну сторінку сайту
E-бібліотека навчальних матеріалів
Електронний каталог бібліотеки ЗДМФУ
Стандартний